Chris Takimoto
Chief Tech/Sci/R&D Officer chez IGM BIOSCIENCES, INC.
Fortune : 910 844 $ au 31/03/2024
Profil
Chris H.
Takimoto is currently the Chief Medical Officer at IGM Biosciences, Inc. He previously held senior positions at Gilead Sciences, Inc., Forty Seven, Inc., Ortho Biotech Oncology Research & Development, and Janssen Global Services LLC.
He also worked as an Associate Professor at the University of Texas Health Science Center at San Antonio.
Takimoto received his undergraduate degree from Stanford University and his doctorate from Yale University and the Yale School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IGM BIOSCIENCES, INC.
0,28% | 14/03/2024 | 94 388 ( 0,28% ) | 910 844 $ | 31/03/2024 |
Postes actifs de Chris Takimoto
| Sociétés | Poste | Début |
|---|---|---|
| IGM BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 29/07/2021 |
Anciens postes connus de Chris Takimoto
| Sociétés | Poste | Fin |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/07/2021 |
| FORTY SEVEN, INC. | Chief Tech/Sci/R&D Officer | 01/04/2020 |
Janssen Global Services LLC
 Janssen Global Services LLC Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Janssen Global Services LLC develops treatments for patients in therapeutic areas of healthcare. The private company is based in Raritan, NJ. | Corporate Officer/Principal | 01/01/2016 |
| Ortho Biotech Oncology Research & Development | Corporate Officer/Principal | 01/01/2010 |
| University of Texas Health Science Center At San Antonio | Corporate Officer/Principal | - |
Formation de Chris Takimoto
| Stanford University | Undergraduate Degree |
| Yale University | Doctorate Degree |
| Yale School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| IGM BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
| Ortho Biotech Oncology Research & Development | |
Janssen Global Services LLC
Janssen Global Services LLC Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Janssen Global Services LLC develops treatments for patients in therapeutic areas of healthcare. The private company is based in Raritan, NJ. | Health Technology |
